These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 10455872)

  • 1. Immune selection after antigen-specific immunotherapy of melanoma.
    Riker A; Cormier J; Panelli M; Kammula U; Wang E; Abati A; Fetsch P; Lee KH; Steinberg S; Rosenberg S; Marincola F
    Surgery; 1999 Aug; 126(2):112-20. PubMed ID: 10455872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
    Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
    Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.
    Kawakami Y; Eliyahu S; Jennings C; Sakaguchi K; Kang X; Southwood S; Robbins PF; Sette A; Appella E; Rosenberg SA
    J Immunol; 1995 Apr; 154(8):3961-8. PubMed ID: 7706734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.
    Zhai Y; Yang JC; Kawakami Y; Spiess P; Wadsworth SC; Cardoza LM; Couture LA; Smith AE; Rosenberg SA
    J Immunol; 1996 Jan; 156(2):700-10. PubMed ID: 8543823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases.
    Panelli MC; Riker A; Kammula U; Wang E; Lee KH; Rosenberg SA; Marincola FM
    J Immunol; 2000 Jan; 164(1):495-504. PubMed ID: 10605047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
    Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
    Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes.
    Seiter S; Monsurro V; Nielsen MB; Wang E; Provenzano M; Wunderlich JR; Rosenberg SA; Marincola FM
    J Immunother; 2002; 25(3):252-63. PubMed ID: 12000867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes.
    Grover A; Kim GJ; Lizée G; Tschoi M; Wang G; Wunderlich JR; Rosenberg SA; Hwang ST; Hwu P
    Clin Cancer Res; 2006 Oct; 12(19):5801-8. PubMed ID: 17020987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients.
    Xu Y; Theobald V; Sung C; DePalma K; Atwater L; Seiger K; Perricone MA; Richards SM
    J Transl Med; 2008 Oct; 6():61. PubMed ID: 18945350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients.
    Mandelcorn-Monson RL; Shear NH; Yau E; Sambhara S; Barber BH; Spaner D; DeBenedette MA
    J Invest Dermatol; 2003 Sep; 121(3):550-6. PubMed ID: 12925214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy.
    Kawakami Y; Rosenberg SA
    Int Rev Immunol; 1997; 14(2-3):173-92. PubMed ID: 9131386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
    Kawakami Y; Robbins PF; Wang X; Tupesis JP; Parkhurst MR; Kang X; Sakaguchi K; Appella E; Rosenberg SA
    J Immunol; 1998 Dec; 161(12):6985-92. PubMed ID: 9862734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.
    Di Pucchio T; Pilla L; Capone I; Ferrantini M; Montefiore E; Urbani F; Patuzzo R; Pennacchioli E; Santinami M; Cova A; Sovena G; Arienti F; Lombardo C; Lombardi A; Caporaso P; D'Atri S; Marchetti P; Bonmassar E; Parmiani G; Belardelli F; Rivoltini L
    Cancer Res; 2006 May; 66(9):4943-51. PubMed ID: 16651452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides.
    Salgaller ML; Afshar A; Marincola FM; Rivoltini L; Kawakami Y; Rosenberg SA
    Cancer Res; 1995 Nov; 55(21):4972-9. PubMed ID: 7585538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy.
    Rivoltini L; Loftus DJ; Barracchini K; Arienti F; Mazzocchi A; Biddison WE; Salgaller ML; Appella E; Parmiani G; Marincola FM
    J Immunol; 1996 May; 156(10):3882-91. PubMed ID: 8621927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions.
    Marincola FM; Hijazi YM; Fetsch P; Salgaller ML; Rivoltini L; Cormier J; Simonis TB; Duray PH; Herlyn M; Kawakami Y; Rosenberg SA
    J Immunother Emphasis Tumor Immunol; 1996 May; 19(3):192-205. PubMed ID: 8811494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in humans.
    Chandran SS; Paria BC; Srivastava AK; Rothermel LD; Stephens DJ; Dudley ME; Somerville R; Wunderlich JR; Sherry RM; Yang JC; Rosenberg SA; Kammula US
    Clin Cancer Res; 2015 Feb; 21(3):534-43. PubMed ID: 25424856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes.
    Dudley ME; Ngo LT; Westwood J; Wunderlich JR; Rosenberg SA
    Cancer J; 2000; 6(2):69-77. PubMed ID: 11069222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced recognition of metastatic melanoma cells by autologous MART-1 specific CTL: relationship to TAP expression.
    Murray JL; Hudson JM; Ross MI; Zhang HZ; Ioannides CG
    J Immunother; 2000 Jan; 23(1):28-35. PubMed ID: 10687135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy.
    Cormier JN; Abati A; Fetsch P; Hijazi YM; Rosenberg SA; Marincola FM; Topalian SL
    J Immunother; 1998 Jan; 21(1):27-31. PubMed ID: 9456433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.